Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder
Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder
批准号:
10751173
负责人:
Alaina Jaster
金额:
$4.16万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
AccidentsAcuteAdultAffectAlcohol consumptionAlcoholsAmphetaminesAnimal ModelAnimalsAssociation LearningBehaviorBehavioralBehavioral ModelBiological AssayBrainCessation of lifeClinicalClinical ResearchClinical TrialsCognitionComplexCritical ThinkingDataDiseaseDoseDrug InteractionsDrug ModulationDrug usageEnterobacteria phage P1 Cre recombinaseExtinctionFemaleFrightFutureGoalsHallucinogensHumanInvestigationKnockout MiceLifeLysergic Acid DiethylamideMemoryMental DepressionMethodsModelingMolecularMolecular TargetMotivationMusNeurobiologyNicotineNucleus AccumbensOpioidOpioid ReceptorOxycodonePatientsPerceptionPharmaceutical PreparationsPharmacologyPharmacotherapyPlayPre-Clinical ModelProcessPsilocybinPsychotropic DrugsPublishingRattusReceptor ActivationRecording of previous eventsRegulationRelapseReportingResearchRewardsRodent ModelRoleScientistSelf AdministrationSensorySerotoninSerotonin Receptor 5-HT2ASignal TransductionStimulantStimulusStructureSubstance Use DisorderSucroseSurveysTechniquesTestingTherapeuticTherapeutic EffectTrainingTryptaminesUnited StatesViral VectorWild Type MouseWritingaddictionbehavioral phenotypingclinically relevantconditioned place preferenceconditioningcostcravingdelivery vehicledrug of abusefrontal lobehippocampal pyramidal neuronhuman modelinterestmaladaptive behaviormaleneural circuitnicotine usenovelopioid misuseopioid use disorderoverdose deathpre-clinicalpreferenceprescription opioid abuseserotonin receptorside effectsuccesssynthetic opioidtargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary
In 2020, 91,799 drug overdose deaths occurred in the United States , over a third of which were
related to synthetic opioids. Opioid use disorder (OUD), like other substance use disorders
(SUD), is characterized maladaptive behavioral allocation away from other rewarding aspects of
life following prolonged use, as well as large rates of relapse. While pharmacotherapies exist for
OUD, they tend to only target the opioid receptors rather than the underlying mechanisms
behind the maladaptive behaviors. Serotonin (5-hydroxytryptamine; 5-HT) is involved in
modulation of cravings and regulation of motivational reward-related behaviors, thought to be
due to a top-down processing method of external and internal stimuli. Serotonin 2A receptors
(5-HT2AR) are widespread throughout the brain and most densely populate layer V pyramidal
neurons in the cortex. These cortical pyramidal neurons project to several subcortical regions,
including the nucleus accumbens, which is associated with the neurobiology of addiction. 5-
HT2ARs are the main target of classic psychedelics, which produce alterations in processes
related to cognition, perception and sensory processing via activation of these receptors. These
compounds may possess the ability to alter behaviors associated with reward-related behaviors,
such as context-induced relapse, which plays a large part in substance use disorders.
Moreover, these compounds are being studied in clinical trials for their ability to treat substance
use disorders. The proposed study will investigate whether a psychedelic can alter drug-related
behaviors and the role of cortical 5-HT2AR in modulation of these behaviors. This study will
focus on tryptamine psychedelic, psilocybin, which has a chemotype very similar to serotonin
that activates mainly 5-HT2AR and 5-HT1Rs. Throughout the proposed study, I will be assessing
the role of the 5-HT2AR by utilizing cre-recombinase viral vector delivery which will allow me to
assess specific loci of 5-HT2AR and how activation of these receptors modulates drug-context
related behaviors. The success of this studies will identify important mechanisms behind this
The success of this studies will identify important mechanisms behind this. The success of this
studies will identify important mechanisms behind this powerful drug class, including circuitry
that could be utilized to develop safe, non-addictive and non-hallucinogenic pharmacotherapies
to treat OUD. The proposed will facilitate my training in molecular techniques and animal
behavioral models as well as give me opportunities to advance my scientific writing, critical
thinking and prepare me for a future as an independent research scientist.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金